Home Increased concentrations of growth factors and activation of the EGFR system in breast cancer
Article
Licensed
Unlicensed Requires Authentication

Increased concentrations of growth factors and activation of the EGFR system in breast cancer

  • Dorte Aa. Olsen EMAIL logo , Troels Bechmann , Birthe Østergaard , Peter A. Wamberg , Erik H. Jakobsen and Ivan Brandslund
Published/Copyright: May 10, 2012

Abstract

Background: In this study the total and phosphorylated amount of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) were measured together with EGFR ligands in tissue samples of breast cancer patients in order to investigate interrelations and possible prognostic values.

Methods: Samples of malignant and non-cancer autologous reference tissue were collected from 415 breast cancer patients. The tissue samples were cut and either paraffin-embedded or homogenized in a lysis buffer to extract the proteins. HER2 was measured using both immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) and ADVIA Centaur. Phosphorylated HER2 and EGFR (pHER2, pEGFR), total EGFR and the ligands: epidermal growth factor (EGF), transforming growth factor-α (TGFα), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EREG) were measured using the Luminex.

Results: The HER2 positivity rate was determined to be 25.2% by the Centaur method vs. 15.8% by IHC and FISH. HER2, HB-EGF, TGFα and AREG were upregulated in cancer tissue as compared with autologous reference tissue while EGFR, pEGFR and EGF were downregulated (p<10–6). pEGFR in autologous reference tissue was negatively correlated to the number of positive lymph nodes and to the tumor size (p=0.0007 and p=0.001, respectively) and furthermore, decreased in the group of mastectomy operated patients as compared with the lumpectomy group (p<10–6). HB-EGF in cancer tissue was positively associated with high grade tumors (p<10–6) and pHER2, HB-EGF and BTC were associated with poor disease free survival (p=0.017, p=0.012 and p=0.0026, respectively).

Conclusions: Our study demonstrated a profound activation of the EGFR system. HB-EGF was increased by factor 10 in cancer tissue and related to the biological aggressiveness of the tumors, and pHER2, HB-EGF and BTC were associated with poor clinical outcome.


Corresponding author: Dorte Aa. Olsen, Department of Clinical Biochemistry, Vejle Hospital Kabbeltoft 25 7100 Vejle, Denmark Phone: +45 79406633, Fax: +45 79406871

Received: 2011-11-8
Accepted: 2012-4-2
Published Online: 2012-05-10
Published in Print: 2012-10-01

©2012 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Masthead
  2. Masthead
  3. Editorials
  4. Cancer epigenomics: moving slowly, but at a steady pace from laboratory bench to clinical practice
  5. Laboratory networking and sample quality: a still relevant issue for patient safety
  6. Reviews
  7. DNA methylation biomarkers and their utility for solid cancer diagnostics
  8. DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer
  9. Global DNA hypomethylation in cancer: review of validated methods and clinical significance
  10. Genetics and Molecular Diagnostics
  11. δ0-Thalassemia in cis of βKnossos globin gene: first homozygous description in thalassemia intermedia Libyans and first combination with codon 39 (C→T) in thalassemia intermedia Tunisian patients
  12. Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish population sample
  13. General Clinical Chemistry and Laboratory Medicine
  14. Effects of sample transportation on commonly requested laboratory tests
  15. Long-term (in)stability of folate and vitamin B12 in human serum
  16. Information comparison of the effects of drugs on laboratory tests in drug labels and Young’s book
  17. First evaluation of Capillarys 2 Flex Piercing® (Sebia) as a new analyzer for HbA1c assay by capillary electrophoresis
  18. Antioxidant and oligonutrient status, distribution of amino acids, muscle damage, inflammation, and evaluation of renal function in elite rugby players
  19. Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluids
  20. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation
  21. Cancer Diagnostics
  22. Increased concentrations of growth factors and activation of the EGFR system in breast cancer
  23. Infectious Diseases
  24. Incidence and significance of elevated lactate in the identification of critically ill patients
  25. Cardiovascular Diseases
  26. Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis
  27. Diabetes
  28. Serum cystatin C as a marker for early detection of chronic kidney disease and grade 2 nephropathy in Japanese patients with type 2 diabetes
  29. Letters to the Editor
  30. Establishing professional phlebotomist group for quality control of the preanalytic variables of clinical laboratory
  31. Application of quality specification based on biological variation in planning quality control strategy
  32. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab
  33. Comparison of relationships between FT4 and log TSH in Access DXI 800 Unicel, Modular E170 and ADVIA Centaur XP Analyzer
  34. Assay-specific pitfalls of catecholamine HPLC assays
  35. Evaluation of automated nucleated red blood cells counting on Sysmex XE5000 and Siemens ADVIA 2120
  36. Evaluation of the immature myeloid information (IMI) by Sysmex XE 2100® hematology analyzer in the identification of blasts of myeloid lineage
  37. Congress Abstracts
  38. Congress of Laboratory Medicine and Clinical Chemistry / 4th Annual Meeting of the Austrian Society for Laboratory Medicine and Clinical Chemistry (ÖGLMKC)
  39. Abstracts of the 2012 Convocation of Experts on Laboratory Quality / Embracing the Need of Continued Vigilance to Assure Quality Outcomes in the Modern Laboratory
Downloaded on 13.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2011-0823/html
Scroll to top button